Tumor deposit serves as a prognostic marker in gastric cancer: A propensity score‐matched analysis comparing survival outcomes

Abstract Background Gastric cancer (GC) treatment is determined by accurate tumor staging. The value of tumor deposit (TD) in prognostic prediction staging system is not yet determined. Methods We retrospectively analyzed clinical information on GC patients who underwent gastrectomy at the Departmen...

Full description

Bibliographic Details
Main Authors: Liang Wenquan, Liu Yuhua, Cui Jianxin, Xi Hongqing, Zhang Kecheng, Li Jiyang, Gao Yunhe, Liu Yi, Zhang Wang, Li Shaoqing, Lu Yixun, Qiao Shen, Xue Wanguo, Qiao Zhi, Chen Lin
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.2963
Description
Summary:Abstract Background Gastric cancer (GC) treatment is determined by accurate tumor staging. The value of tumor deposit (TD) in prognostic prediction staging system is not yet determined. Methods We retrospectively analyzed clinical information on GC patients who underwent gastrectomy at the Department of General Surgery of the Chinese PLA General Hospital from July 2014 to June 2016. Propensity score matching (PSM) was performed to reduce the possibility of selection bias according to the presence of TD. Results Of the 1034 GC patients, 240 (23.21%) presented with TD, which was associated with younger age and larger tumor size (all P < .05). TD‐positive patients had a worse survival than TD‐negative patients before (P < .001) and after (P = .017) matching. Multivariable analysis showed that mortality risk of patients with TD increased by 58%, 62%, 37%, and 40% in the crude (HR = 1.58, 95% CI 1.32‐1.89, P < .001), adjusted I (HR = 1.62, 95% CI 1.35‐1.94, P < .001), adjusted II (HR = 1.37, 95% CI 1.13‐1.66, P = .001), and adjusted III (HR = 1.40, 95% CI 1.16‐1.68, P < .001) models before matching. Similarly, in the PSM cohort patients with TD had worse prognosis in the crude (HR = 1.32, 95% CI 1.07‐1.63, P = .011), adjusted I (HR = 1.35, 95% CI 1.09‐1.67, P = .005), adjusted II (HR = 1.26, 95% CI 1.00‐1.58, P = .049), and adjusted III (HR = 1.33, 95% CI 1.07‐1.65, P = .010) models. TD had a similar value range between N1 and N2 stages among different models. Conclusions Among GC patients, TD is associated with survival and may have a role in the staging of patients.
ISSN:2045-7634